Entities / Company
ALK-Abelló.
Danish pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 28
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Supply of auto-injectors is facing shortages, coinciding with reports that severe allergies affect 300,000 people in Austria.Some support1 report
-
NICE recommended ALK-Abelló's allergy tablets, which are now available through the National Health Service.Some support1 report
-
ALK-Abelló received approval from Health Canada and launched its product neffy in the Canadian market.Some support1 report
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around ALK-Abelló this week
News at the entities that move ALK-Abelló most-
Health Canada StructuralCanadian Blood Services faces union calls for contract termination after Health Canada issued a non-compliance rating.Moves ALK-Abelló
-
Official guidance informed by the NIHC is being used in both England and Scotland to gather testimonies regarding ME/CFS treatment.
Moves ALK-Abelló
-
National Health Service StructuralLeading commission into adult social care in England discusses NHS withdrawal and National Care Service proposals.Moves ALK-Abelló
Connections
The 4 strongest of 28, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Edward Jordan Structural
Edward Jordan holds the executive vice president role for ALK North America.
-
Health Canada Structural
Health Canada grants regulatory approval to ALK-Abelló, establishing a formal regulatory dependency for market access.
-
National Health Service Structural
ALK-Abelló supplies products (tablets) that are procured and made available through the National Health Service.
-
NICE formally recommended ALK-Abelló's allergy tablets, influencing their market access in the UK.
History
Events by the month they beganAugust 2026
3 events- Supply of auto-injectors is facing shortages, coinciding with reports that severe allergies affect 300,000 people in Austria.
- NICE recommended ALK-Abelló's allergy tablets, which are now available through the National Health Service.
- ALK-Abelló received approval from Health Canada and launched its product neffy in the Canadian market.